Compare NL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NL | TLSI |
|---|---|---|
| Founded | 1891 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 270.2M |
| IPO Year | 1994 | 2020 |
| Metric | NL | TLSI |
|---|---|---|
| Price | $6.89 | $5.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 41.0K | ★ 165.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $158,285,000.00 | $45,151,000.00 |
| Revenue This Year | $9.32 | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $25.00 | ★ N/A |
| Revenue Growth | 8.46 | ★ 53.41 |
| 52 Week Low | $5.04 | $2.20 |
| 52 Week High | $8.60 | $7.95 |
| Indicator | NL | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 56.23 |
| Support Level | $5.67 | $4.21 |
| Resistance Level | $8.60 | $5.58 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 77.11 | 57.47 |
NLI Holdings Inc, formerly known as NL Industries Inc, is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.